Table 1 Post-infarction angiotensin converting enzyme-inhibitor trials
| Â | Unselected post-infarction patients | Post-infarction patients with left ventricular dysfunction | |||||
|---|---|---|---|---|---|---|---|
Trial | CONSENSUS II | GISSI-3 | ISIS-4 | SAVE | AIRE | SMILE | TRACE |
[Reference no] | [16] | [8] | [7] | [10] | [12] | [9] | [11] |
Drug | Enalapril | Lisinopril | Captopril | Captopril | Ramipril | Zofenopril | Trandolapril |
Number of patients | 6090 | 19,394 | 58,050 | 2231 | 2006 | 1556 | 1749 |
Target dose | 20 mg × 1 | 10 mg × 1 | 50 mg × 2 | 50 mg × 3 | 5 mg × 2 | 30 mg × 2 | 4 mg × 1 |
Inclusion criteria | AMI | AMI | AMI | LVEF < 40% | Signs or | Anterior wall | Low wall |
| Â | consecutively | consecutively | consecutively | Â | symptoms of | AMI without | motion index |
| Â | Â | Â | Â | Â | heart failure | thrombolytics | score |
Follow-up time | 1.5-6 months | 6 weeks | 5 weeks | 24-60 months | 6-30 months | 6 weeks | 24-50 months |
| Â | (trial stopped) | Â | Â | Â | Â | Â | Â |
Mortality reduction | P: 10.2% | P: 7.1% | P: 7.7% | P: 25% | P: 23% | P: 10.6% | P : 42.3% |
| Â | T: 11.0% | T: 6.3% | T: 7.2% | T: 20% | T: 17% | T: 7.1% | T: 34.7% |
Risk reduction | -10 % | 12% | 7% | 19% | 27% | 25% | 22% |
(95% CI) | (-29 to 7%) | (1% to 21%) | (1% to 13%) | (3% to 32%) | (11% to 40%) | (-11% to 60% | (9% to 33%) |
Level of significance | P = 0.26 | P = 0.03 | P = 0.02 | P = 0.019 | P = 0.002 | P = 0.19 | P = 0.001 |